Cidara Therapeutics, Inc.
CDTX
Hisse Senetlerindeki Sıralama
#3185
Cidara Therapeutics, Inc. is a biotechnology company specializing in the... Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.
Hisse Fiyatı
$221.38
Son senkronizasyon: 2026-01-08
Piyasa Değeri
$5.61B
Değişim (1 gün)
0.00%
Değişim (1 yıl)
118.07%
Ülke
US
Ticaret Cidara Therapeutics, Inc. (CDTX)
Kategori
Healthcare
Cidara Therapeutics, Inc. (CDTX) için kazanç
Sep 2025 itibarıyla kazanç TTM: $-184.80M
Cidara Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut kazancı $-184.80M'dir. 2023 yılında şirket $-25.07M kazanç elde etti, bu 2022 yılındaki $-33.31M kazanca göre önceki yıla göre artış. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Cidara Therapeutics, Inc. için kazanç geçmişi 2012 - 2026
Her yılın sonundaki kazanç
| Yıl | Kazanç | Değiştir |
|---|---|---|
| 2026 (TTM) | $-184.80M | 8.52% |
| 2024 | $-170.29M | 579.40% |
| 2023 | $-25.07M | -24.76% |
| 2022 | $-33.31M | -21.56% |
| 2021 | $-42.47M | -41.11% |
| 2020 | $-72.11M | 75.49% |
| 2019 | $-41.09M | -30.37% |
| 2018 | $-59.02M | 5.90% |
| 2017 | $-55.73M | 15.70% |
| 2016 | $-48.17M | 49.61% |
| 2015 | $-32.19M | 170.67% |
| 2014 | $-11.89M | 784.97% |
| 2013 | $-1.34M | 69.70% |
| 2012 | $-792.00K | 0.00% |
Benzer şirketler veya rakipler için kazanç
| Şirket | Kazanç | Kazanç Farkı | Ülke |
|---|---|---|---|
| $5.27B | -2,954.38% |
US
|
|
| $-3.09B | 1,570.45% |
US
|
|
| $-4.02B | 2,073.27% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -1,155.55% |
NL
|
